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Introduction {#sec1}
============

The class IA PI3Ks are obligate heterodimers, consisting of a p110 catalytic subunit and a p85-type regulatory subunit. They trigger a cascade of mammalian signaling pathways downstream of receptor tyrosine kinases (RTKs) by generating the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP~3~), which recruits effectors to lipid membranes ([@bib17; @bib50]). Among PI3Ks, the p110β isotype is uniquely activated by both RTKs and Gβγ heterodimers ([@bib34; @bib36; @bib19]). p110β controls platelet activation and thrombosis ([@bib24; @bib39]), DNA replication ([@bib38]), and male fertility ([@bib12]) and contributes to insulin signaling ([@bib11; @bib31]). Moreover, p110β has oncogenic functions in PTEN-negative tumors and in ERBB2-dependent tumors ([@bib26; @bib11]).

All class IA PI3Ks can induce oncogenic transformation ([@bib54; @bib29]). Consequently, p110α, p110β, and p110δ need to be tightly regulated. This is achieved by the regulatory subunits, which stabilize the p110, inhibit its basal activity, and facilitate recruitment and activation downstream of RTKs. There are five p85-type regulatory subunits (p85α, p85β, p55γ, p55α, and p50α) encoded by three genes. All regulatory subunits have a coiled-coil inter-SH2 domain (iSH2) that binds tightly to the adaptor-binding domain (ABD) of the p110 catalytic subunit ([Figures 1](#fig1){ref-type="fig"}A and [S1](#app3){ref-type="sec"}). The iSH2 is flanked by the two SH2 domains, nSH2 and cSH2. Upon RTK activation, the p85 SH2 domains bind to a phosphotyrosine (pY)-containing consensus sequence, pYXXM, in RTKs and pY-phosphorylated adaptor proteins ([@bib8; @bib47]). Although, in general, short pY motifs from RTKs provide tight binding to SH2 domains ([@bib46; @bib44; @bib22]), the recent structure of the phospholipase Cγ (PLCγ) SH2 domains with the activated tyrosine kinase domain of FGFR1 has elegantly challenged the notion that short, linear polypeptides can recapitulate the SH2 interaction with their native targets ([@bib2]).

Mutations in the p85α regulatory subunit are frequent in several cancers and promote cell survival and oncogenesis in a p110-dependent manner ([@bib42; @bib6; @bib25]). Binding SH2 domains of a p85 regulatory subunit to RTKs relieves the basal inhibition and leads to activation of the p110 catalytic subunit ([@bib1; @bib20]). The minimal regulatory subunit capable of inhibiting p110α consists of the nSH2 and iSH2 (p85-niSH2) ([@bib53]). The role of the cSH2 has remained elusive, since it is required for full activation of p110α in the context of the full-length p85 regulatory subunit ([@bib45]), but it has no role in inhibiting basal activity of p110α ([@bib53]). Several cSH2 truncated versions of p85α have been isolated from cancer cell lines, including p65 (lacking the cSH2 and part of the iSH2) and p76 (lacking the C-terminal 85 residues of the cSH2) ([@bib27; @bib28]). Both truncations are associated with increased PI3K activity, contributing to cellular transformation.

Intrigued by the oncogenic potential of all p110 isoforms, we tried to uncover the critical inhibitory mechanisms that keep these enzymes under control. We found that the cSH2, in addition to nSH2, has a key role in p110β inhibition. To understand the basis for the unanticipated inhibition by the cSH2, we determined the crystal structure of the p110β catalytic subunit in a complex with a regulatory construct consisting of the iSH2 and cSH2 p85-icSH2. The structure of this complex shows that the cSH2 interacts with a "regulatory arm" at the C terminus of the kinase domain. This contact inhibits the enzyme and the inhibition can be relieved both in vitro and in cells by RTK phosphopeptides or by a point mutation in the cSH2. The cSH2 surface that makes the inhibitory contact with p110β does not coincide with the pY-binding site, providing a structural basis for the requirement of extended pYXXM RTK motifs to relieve p110β inhibition.

Results {#sec2}
=======

Inhibition of p110β by p85β nSH2 and cSH2 Domains {#sec2.1}
-------------------------------------------------

Given the substantial evidence for an oncogenic potential of p110β (reviewed in [@bib51]), we focused on the regulation of this isoform. We assayed the ability of a series of p85 deletion variants to inhibit full-length p110β as well as the extent to which this inhibition is relieved by RTK phosphopeptides. By using several types of substrates---liposomes, soluble lipids, and water---we tried to deconvolute regulation arising from effects on membrane binding, monomeric lipid interaction, and the intrinsic chemistry of the phosphoryl transfer.

We compared the catalytic activity of purified recombinant proteins using either a high-throughput fluorescence polarization assay, which measures the production of ADP ([@bib30]) ([Supplemental Experimental Procedures](#app3){ref-type="sec"}), or assays that measure PIP~3~ production directly (using radioactive assays and mass spectroscopy). The activity of the p110β catalytic subunit with the lipid substrate diC8-PIP~2~/POPS is strongly inhibited by a p50-like regulatory subunit core that contains both the nSH2 and cSH2, linked through the iSH2 (nicSH2) ([Figure 1](#fig1){ref-type="fig"}B). The basal activity of the p110β/p85β-nicSH2 is considerably lower than a complex containing only the iSH2 or a construct of the catalytic subunit without the regulatory subunit, ΔABD-p110β. We used ΔABD-p110β as a substitute for the free full-length catalytic subunit, since the latter cannot be stably expressed in insect cells ([@bib4]).

To dissect the regulatory roles of each of the three domains present in the p85β-nicSH2 construct, we assayed further truncation variants of p85β for their ability to inhibit the basal activity of p110β. Our results clearly show that both nSH2 and cSH2 contribute significantly to inhibition of p110β. Each SH2 domain inhibits the enzyme relative to the complex containing only iSH2 ([Figure 1](#fig1){ref-type="fig"}B). Compared to the complex with both SH2 domains (nicSH2), the absence of either the nSH2 or the cSH2 leads to enzyme activation as measured by ADP formation ([Figure 1](#fig1){ref-type="fig"}B) or by PIP~3~ formation using radioactive assays or mass spectroscopy ([Figures S2](#app3){ref-type="sec"}A--S2C and [S3](#app3){ref-type="sec"}A). This surprising inhibitory effect of the cSH2 on the p110β basal activity stands in contrast to p110α, which was reported previously to be inhibited by the nSH2 but not by the cSH2 ([@bib53]).

Activation by RTK Bis-Phosphorylated Peptide {#sec2.2}
--------------------------------------------

The addition of a bis-phosphopeptide (PDGFR 735--767, with pY740 and pY751, abbreviated as pY~2~) stimulates kinase activity (measured by ADP formation) by all three complexes containing SH2 domains (nicSH2, niSH2, or icSH2), but did not affect the activity of p110β/p85β-iSH2 or ΔABD-p110β ([Figure 1](#fig1){ref-type="fig"}B). Similarly, pY~2~ stimulates lipid kinase activity of p110β SH2-containing complexes, as measured directly by PIP~3~ formation ([Figures S2](#app3){ref-type="sec"}A--S2C) using a radioactive phosphorylation assay ([@bib32]). We find that the fold of activation by pY~2~ depends greatly on the type of lipid substrate and lipid presentation (10-fold activation with a defined mixture of "brain lipids" \[composed of 5% PIP~2~, 20% PS, 15% PC, 45% PE, 5% sphingomyelin, and 10% cholesterol\] and 16-fold with diC8-PIP~2~/POPS liposomes, measured by PIP~3~ formation for p110β/p85β-nicSH2 \[[Figures S2](#app3){ref-type="sec"}A--S2C\]). The variation in the activation fold is not surprising given the long history of reports on the huge effect of the lipid composition and vesicle size on the basal activity of PI3Ks (e.g., micelle/vesicle composition, vesicle size, PI versus PIP~2~, etc.) ([@bib23; @bib10; @bib7; @bib3]). Previously reported activation by phosphopeptides range from 2- to 4-fold for immunoprecipitated p110α/p85α, using pure PI substrate ([@bib53; @bib40]), to 20- to 40-fold for purified recombinant p110α/p85α, p110β/p85α, and p110δ/p85α using PIP~2~-containing liposomes ([@bib36]).

p110β complexes can also phosphorylate a soluble lipid substrate diC8-PIP~2~, although less efficiently than liposomal substrate. Interestingly, phosphorylation of monomeric diC8-PIP~2~ is still activated by pY~2~, with a change in EC~50~ upon peptide addition ranging from 2- to 8-fold, depending on the regulatory construct ([Figure 1](#fig1){ref-type="fig"}C).

All PI3Ks have ATPase activity in addition to their lipid kinase activity ([@bib41; @bib30]) that can be observed when measuring ADP formation in the absence of lipid substrate ([Figure 1](#fig1){ref-type="fig"}D); however, the ATPase activity is quite low compared with the lipid kinase activity. We have verified that this ATPase activity is not due to a contaminating ATPase, because it can be fully inhibited by a kinase-dead mutation (D913N) in the recombinant enzyme or by a PI3K-specific inhibitor ([Figure S3](#app3){ref-type="sec"}B). This ADP-formation assay has enabled us to expand our insight into mechanisms of PI3K regulation by determining activity both in the presence and absence of lipid substrates.

Structural Basis for p110β Inhibition by cSH2 and Release of Inhibition by Phosphopeptide {#sec2.3}
-----------------------------------------------------------------------------------------

In an attempt to unravel the structural basis for the inhibition of p110β by the cSH2, we crystallized full-length mouse p110β in a complex with the mouse p85β-icSH2 (residues 423--722) in the presence of the PI3K inhibitor GDC-0941. The structure was refined at 3.3 Å resolution. There is one copy of a 1:1 p110β/p85β complex in the asymmetric unit, and the density for GDC-0941 is clearly visible (see [Table S1](#app3){ref-type="sec"} for contacts). Crystallographic statistics are given in [Table 1](#tbl1){ref-type="table"}.

This complex shows that both the iSH2 and cSH2 are ordered and interact with the p110β catalytic subunit. In the overall arrangement of the two subunits, the long coiled coil of the iSH2 slots into the large arch formed by the catalytic subunit, while the cSH2 nestles against the C-terminal region of the kinase domain ([Figure 2](#fig2){ref-type="fig"}A). The structure of the complex reveals possible underlying mechanisms of inhibition by the cSH2. In contrast to the nSH2 of p85α, which is in contact with three domains of p110α (C2, helical, and kinase domains) ([@bib37; @bib40]), the cSH2 of p85β contacts only the C lobe of the p110β kinase domain. The solvent accessible surface area buried by the cSH2/p110β interface (1264 Å^2^) is smaller than the nSH2/p110α interface (1793 Å^2^). Our structure shows that a cSH2 loop (Ala674 to Tyr680), which was described as a protrusion at the surface of cSH2 ([@bib21]), forms the main contact point with the p110β. This loop interacts with a double layer of helical pairs, the Kα7/Kα8 and the C-terminal Kα11/Kα12 of the kinase domain ([Figures 2](#fig2){ref-type="fig"}B and [S2](#app3){ref-type="sec"}D). We will refer to each of these helical pairs as an "arm" and the loop between the two helices as an "elbow." The Kα11/Kα12 elbow is marked by Ser1046, which is at the center of a hydrophobic groove between the two elbows, including residues Tyr956, Ile959, and Leu1043. This hydrophobic groove accommodates Tyr677 in βF of the cSH2 (SH2 secondary structure nomenclature follows the description in [@bib16]), and Ser1046-p110β is positioned to form a potential hydrogen bond to the side chain of Tyr677-p85β. Curiously, this conserved tyrosine in the cSH2 is an insertion relative to the nSH2 ([@bib21]). This unique feature suggests distinct regulatory mechanisms by the nSH2 and cSH2. Other contacts between the cSH2 and the catalytic subunit, such as the potential hydrogen bond between the side chain of Glu675 in the cSH2 and the backbone of Asn969 in the Kα7/Kα8 elbow in p110β, may also contribute to the binding.

A comparison of all class IA PI3K structures suggests this inhibitory mechanism by cSH2 is likely to be important for both p110β and p110δ. Interestingly, in p110α, the Kα7/Kα8 elbow is two residues longer relative to p110β and p110δ. Therefore, the p110α elbow might clash with residues from the cSH2-p85β protrusion (674-AlaGluPro-676) ([Figure 2](#fig2){ref-type="fig"}C), contributing to the reported lack of inhibition of p110α by the cSH2. Consistent with this, when we replaced the Kα7/Kα8 elbow of p110β with the elbow of p110α, we found that the mutant is about 2-fold more active than the wild-type p110β ([Figure S3](#app3){ref-type="sec"}C).

There is a notable difference between the ways in which the nSH2 and cSH2 of p85 bind the p110 catalytic subunit. The pY-binding site on the nSH2 is buried in the contact with the helical domain (residues 542--546 in p110α), suggesting immediately how phosphopeptide binding releases nSH2 inhibitory effects on p110α ([@bib37]). In contrast, the pY-binding site on the cSH2 is exposed and not buried in the interface with the p110β ([Figure 2](#fig2){ref-type="fig"}D). Superposition of the cSH2 bound to a PDGFR phosphopeptide (PDB ID: 1H9O) ([@bib43]) suggests that a peptide should have more than four residues following the pY in order to break the cSH2/p110β contact. Indeed, we found that three different RTK phosphopeptides with seven residues following the pY (pY + 7) activated the p110β/p85β-icSH2 complex, whereas pY + 4 peptides failed to activate this complex ([Figure 2](#fig2){ref-type="fig"}E). Nevertheless, all six peptides activated the p110β/p85β-niSH2 complex to a similar level. These results suggest that the fundamental differences between regulation by p85 nSH2 and cSH2 may confer much greater contextual specificity of PI3K activation by RTKs than had been anticipated. Further mapping of PDGFR-derived phosphopeptides shows that inhibition of p110β/p85β-icSH2 is relieved by pY + 5 or longer phosphopeptides ([Figure S3](#app3){ref-type="sec"}D). In addition, relief of inhibition by pY + 5 peptides is dependent on the residue identity at the +5 position ([Figure S3](#app3){ref-type="sec"}D). The longer phosphopeptides (pY + 5 to pY + 7) are more efficient at disinhibiting the enzyme, despite the fact that they have lower affinity for the p110β/p85β complex compared to the short phosphopeptide (pY + 4) ([Figure S3](#app3){ref-type="sec"}E). This is consistent with the longer peptides having to compete with p110β for binding to the cSH2, whereas the pY + 4 peptide binds to the cSH2 without displacing the p110β.

Effect of Contact Mutation on Basal Activity and RTK Activation {#sec2.4}
---------------------------------------------------------------

The structure of the PI3Kβ complex has identified Tyr677 in the p85β cSH2 as the major contact with the elbow region of the p110β. We mutated Tyr677 to alanine to see if this contact regulates p110β activity. The mutant p110β/p85β-icSH2-Y677A complex in the absence of pY~2~ is more active than the wild-type p110β/p85β-icSH2, and it is not activated by pY~2~ ([Figure 3](#fig3){ref-type="fig"}A). Similarly, the p110β complex with nicSH2-Y677A, a regulatory construct containing wild-type nSH2 but mutant cSH2-Y677A, has a basal activity higher than the wild-type ([Figure 3](#fig3){ref-type="fig"}B), demonstrating that the inhibitory grip of the cSH2 on p110β can be released by a single mutation in the cSH2. Mutation of another residue, E675A, from the AlaGluPro sequence preceding Tyr677, partially relieves cSH2-mediated inhibition ([Figure S3](#app3){ref-type="sec"}F), consistent with this residue forming part of the interface with the p110β subunit. Alanine from the AlaGluPro sequence in p85α was found mutated in a colorectal cancer (A682V in p85α) ([@bib25]). This mutation slightly activates p110β ([Figure S3](#app3){ref-type="sec"}F).

Mutation L1043H in the hydrophobic patch on the surface of p110β that accommodates Tyr677 also increased basal activity, consistent with diminished grip of the cSH2 ([Figure S3](#app3){ref-type="sec"}G). Interestingly, the p110β-L1043H mutant, which is the reverse of the oncogenic H1047L in p110α, has a lower activity than wild-type p110β in the presence of pY~2~.

All Three Types of Regulatory Subunits Modulate p110β Activity via the Same Contact {#sec2.5}
-----------------------------------------------------------------------------------

Given the differential abundance and tissue distribution of the p85-related regulatory subunits, we examined whether three human regulatory subunits, p85α, p85β, and p55γ, could downregulate human p110β via their cSH2 domains. We found that pY~2~ significantly stimulated the activity of p110β bound to the icSH2 from any of the three regulatory subunits ([Figure 4](#fig4){ref-type="fig"}A). Mutation of the conserved tyrosine in p85α, p85β, and p55γ, equivalent to Tyr677 in Mmp85β, released the inhibition of p110β for all three complexes ([Figure 4](#fig4){ref-type="fig"}A). Moreover, these tyrosine-mutated icSH2 heterodimers were not significantly activated by pY~2~. This suggests that tyrosine in βF1 of the cSH2 represents the major point of contact to the p110β catalytic subunit for all three regulatory subunits. Therefore, all regulatory subunits could potentially modulate the activity of the ubiquitously expressed p110β.

Mutation of a Contact Residue in p85α Increases Downstream Signaling in Cells {#sec2.6}
-----------------------------------------------------------------------------

Protein kinase B (PKB or Akt) activation is directly related to the activity of class I PI3Ks, via PIP~3~, which promotes phosphorylation of PKB on Thr308 and Ser473 ([@bib49]). Cotransfection of HEK293T cells with human wild-type p110β and p85α-Y685A mutant resulted in a 2-fold increase in PKB phosphorylation relative to the wild-type heterodimer ([Figures 4](#fig4){ref-type="fig"}B and [S4](#app3){ref-type="sec"}A). A p110β/p85α-N564D heterodimer, carrying a somatic mutation previously demonstrated to potently activate the PI3K signaling pathway ([@bib25]), also showed an increase in phosphorylation of PKB Ser473 ([Figure 4](#fig4){ref-type="fig"}B) and Thr308 ([Figure S4](#app3){ref-type="sec"}A). We also quantified the amount of PIP~3~ in cells to have a direct measure of PI3K activity. Our data are consistent with both mutants increasing PI3K downstream signaling ([Figure S4](#app3){ref-type="sec"}B).

Effect of Kinase Domain C-Terminal Truncation on Activity {#sec2.7}
---------------------------------------------------------

The cSH2 is in contact with C-terminal helix Kα12, suggesting that Kα12 could be implicated in the regulation of p110 by the cSH2. In the class III PI3K Vps34, the C-terminal helix (Kα12) plays a critical role in catalysis ([@bib41]). The Vps34 structure seems to be in an active conformation, with the C-terminal helix pointing away from the catalytic domain and His807 (from the DRH motif) pointing toward the active site ([Figure 5](#fig5){ref-type="fig"}A). In our PI3Kβ structure, the C-terminal helix folds over the catalytic loop, presumably locking it in a closed, inactive conformation, and His915 from the DRH motif points away from the active site.

To test the importance of Kα12 in p110β, we made a truncation lacking the C-terminal 17 residues, p110β-ΔCter. This deletion mutant had very low basal activity with diC8-PIP~2~/POPS ([Figure 5](#fig5){ref-type="fig"}B) and no measurable activity with the "brain lipids" ([Figure S3](#app3){ref-type="sec"}A). In cells, this mutant showed PKB phosphorylation levels similar to the vector control ([Figure 4](#fig4){ref-type="fig"}B). Therefore, the C terminus is important for p110β activity both in vitro and in cells. Interestingly, the ATPase activity in the absence of lipid substrate was increased for the C-terminally truncated p110β ([Figure 1](#fig1){ref-type="fig"}D). In Vps34, we have shown that the analogous C-terminal helix has dual roles: promoting membrane binding and lipid substrate interaction, while suppressing off-pathway activity in the absence of lipid substrate ([@bib41]). Our data suggest a similar role for the C-terminal helix in p110β. By clamping this C terminus, the cSH2 likely inhibits the enzyme by preventing both productive lipid binding and phosphoryl transfer.

Structural Basis for p110β Regulation by iSH2 of p85β {#sec2.8}
-----------------------------------------------------

The iSH2 forms important inhibitory contacts with the p110α catalytic subunit ([@bib52]). Compared to the other class I PI3Ks, the p110β catalytic subunit exhibits an ordered activation loop (residues 930--955), although the side-chain density is poor. This loop is responsible for substrate specificity ([@bib5]). Our structure shows that the long activation loop extends all the way to the iSH2, resulting in the close vicinity of Asp455 in the iSH2-p85β (Asp464-p85α) with both Phe943 and Lys942-p110β ([Figure 6](#fig6){ref-type="fig"}A). This interaction could potentially restrict the flexibility of the activation loop and thereby contribute to inhibiting the enzyme. Mutation D464H-p85α, which was found in glioblastoma ([@bib42]), could affect interaction with Phe943 and Lys942, thereby releasing the grip of iSH2 on the activation loop.

In addition to the activation loop, p85-iSH2 contacts the ABD and C2 domains of p110β differently from the p110α/p85α complex ([Figures 6](#fig6){ref-type="fig"}B and 6C). Previous results for p110α have shown unambiguously that the iSH2/C2 contact is inhibitory ([@bib52]). Two of the contact areas involve iSH2 residues that are mutated in p85α subunit in glioblastomas and were shown to activate p110α, p110β, and p110δ in vitro and in vivo ([@bib42; @bib25; @bib52]). The Asp551-p85β, equivalent to Asp560-p85α (mutated to tyrosine in cancer), interacts with the Ser457 and Ser458 in the Cβ7/Cβ8 loop from the C2 domain and possibly also with the poorly ordered CBR1 loop ([Figure 6](#fig6){ref-type="fig"}C). D560Y mutation could disrupt the interactions this residue makes with the C2 domain. Asn555-p85β, equivalent to Asn564-p85α (mutated to lysine or aspartic acid in cancers), interacts with the largely disordered CBR3 (Cβ5/Cβ6 loop) ([Figure 6](#fig6){ref-type="fig"}C). CBR3 is rich in basic residues that are important for PI3K activity in vivo, probably through their interaction with the phospholipid membranes ([@bib15]). The iSH2 contact with CBR3 may affect the membrane interaction.

The ABD-p110β retains the extensive contacts with iSH2-p85β seen previously in p110α/p85α-iSH2, resulting in 2269 Å solvent-accessible surface area being buried at the interface ([Figure 6](#fig6){ref-type="fig"}B). Among the residues in contact is Asn518-p85β, which is conserved in all regulatory subunits. The equivalent residue in p85α, Asn527, was found mutated to lysine in colorectal cancer ([@bib25]). The structure suggests mutation to lysine would result in a steric clash with the backbone of the Aβ1/Aβ2 loop, thus possibly affecting the primary interaction between ABD and iSH2. A major difference from p110α/iSH2 is seen in the ABD-RBD linker, where the Lα1 and Lα1′-p110β, in particular His129-p110β, are much closer to the Glu476-iSH2 than the corresponding residues in p110α ([Figure 6](#fig6){ref-type="fig"}B). Such differences could contribute to subtle variations in binding of iSH2 to distinct p110 subunits.

Discussion {#sec3}
==========

We propose three extrinsic "brakes" on the basal activity of p110β exerted by the nSH2, cSH2, and iSH2 domains of the regulatory subunit ([Figure 7](#fig7){ref-type="fig"} and [Movie S1](#app3){ref-type="sec"}). The nSH2 interacts with the C2, helical, and the kinase domains of p110 and provides one brake. The second brake is the contact of the cSH2 with the C lobe of the kinase domain. This inhibitory cSH2 interaction distinguishes p110β from p110α ([@bib53]), and our structure suggests a possible explanation for this difference. The third brake is provided by the iSH2, which nestles under the arch formed by the catalytic subunit and forms inhibitory contacts with the C2 domain ([@bib52]). Its mutations in several types of tumors lead to dramatic upregulation of all class IA isozymes. While p110β activity is inhibited by the engagement of three brakes, p110α appears to have only two brakes (nSH2 and iSH2), suggesting that p110α is poised to have greater activity when one of the brakes is lost by mutation. The inhibition of p110β by both SH2 domains of the p85 subunit may explain observations that p110β is less responsive to RTK stimulation in some cells ([@bib34; @bib36; @bib19]).

The inhibitory effect of the cSH2 could be explained by its contacts with the C-terminal region of the kinase domain. In our crystal structure, the kinase domain of the catalytic subunit exhibits the signatures of an inactive conformation. The contacts of the cSH2 with the regulatory elements surrounding the activation and catalytic loops, i.e., helices Kα11/Kα12 and Kα7/Kα8 forming the double-layer regulatory arm, could possibly pin the catalytic and activation loops into an inactive conformation and prevent the C-terminal helix from swinging out to its active conformation. By affecting the C-terminal helix conformation, the cSH2 may also affect membrane binding. In the primordial class III PI3K Vps34, the equivalent C-terminal helix interacts with membranes and its deletion abolishes enzyme activity ([@bib41]). Similarly, we show here that the C terminus in p110β is critical for lipid kinase activity.

Interestingly, the primary interaction site of p110β with the cSH2 is part of a regulatory "square" composed of helices Kα10, Kα11, and Kα12, which were described as three sides of an imaginary rectangle ([@bib35]). While the cSH2 contacts Kα11 and Kα12, the nSH2 interacts with Kα10. As this square envelops the key loops for catalysis, any changes in the conformation of the square could possibly lead to allosteric regulation of the active site, either changing the affinity for lipid substrate or facilitating phosphoryl transfer. In fact, somatic mutations in p110α in human tumors cluster on the perimeter of the square, suggesting the importance of this square in the regulation of the enzyme ([Figure S5](#app3){ref-type="sec"}). Other proteins may also regulate PI3Ks through interactions with the regulatory square ([Figure S6](#app3){ref-type="sec"}).

The inhibition of p110β by the cSH2 can be released upon binding to RTK phosphopeptides. However, the way phosphopeptide breaks the contact between p110 and the SH2 domains is distinct for the nSH2 and cSH2 ([Movie S2](#app3){ref-type="sec"}). The pY-binding site on the nSH2 is buried in the interface with the catalytic subunit, thus pY binding breaks the contact by direct competition. In contrast, the pY-binding site on the cSH2 is exposed, and displacement of the cSH2 from the catalytic subunit requires five or more residues C-terminal to the pY. This means that various tyrosine-phosphorylated receptor kinases and adaptor proteins upstream of PI3Ks could have different potencies to displace the cSH2 inhibitory contact.

We find that the activity of p110β/p85-niSH2 and p110β/p85-icSH2 complexes with soluble lipid substrate as well as with water (ATPase activity in the absence of a lipid substrate) is enhanced in the presence of pY~2~. This suggests that neither the nSH2 nor the cSH2 exerts its inhibition exclusively by affecting membrane binding. At least part of the activation is due to conformational changes in the catalytic elements caused by the dislodging of the SH2 domains from the catalytic subunit upon binding to phosphopeptide. Nevertheless, the highest level of activation is observed with membrane substrates, suggesting changes in membrane binding could also contribute to maximal activation.

Overexpression of wild-type p110β causes oncogenic transformation of cells, whereas wild-type p110α does not ([@bib29]). There is more than one structural feature of the catalytic subunit that could contribute to intrinsic oncogenic potential. One of them is the presence of Leu1043 in the C terminus of p110β (and p110δ), equivalent to His1047 in p110α. We have shown that the L1043H-p110β mutation decreases enzyme activity in the presence of RTK phosphopeptide. Conversely, naturally occurring mutations of this residue to a leucine in p110α display increased activity and are highly oncogenic. It seems that p110α has an intrinsic inhibitory mechanism involving His1047 at the elbow region, whereas p110β and p110δ need an extrinsic brake, provided by the cSH2, to inhibit their activity. Other structural features, such as the more basic character of the putative membrane-binding CBR loops in the C2 domain of p110β and p110δ versus p110α, could also affect oncogenic potentials. Indeed, mutations of basic residues in CBR3 of p110δ ([@bib15]) or mutation of a basic residue in CBR1 of p110β ([@bib14]) dramatically reduced their transformation potency. The iSH2 inhibitory interaction with the C2 domain can also provide a differential brake on p110 activity. It was recently shown that the iSH2-C2-mediated inhibition is more pronounced in p110α than in p110β ([@bib14]). This constitutes an SH2-independent brake on p110 activity.

In addition to its lipid kinase activity, PI3Ks also exhibit kinase activity toward peptides ([@bib5]) and water. The ability to bind different substrates suggests plasticity in the active site, which is reflected by the weak density of the activation loop (i.e., substrate-binding loop) in our structure. Thus, we expect that the conformation of the activation loop observed in our structure would be changed upon substrate binding.

Besides regulation by interaction with RTKs, the activity of the p110 catalytic subunit could also be modulated by the posttranslational modifications of the regulatory subunits. When we map the reported p85 modification sites on the structure, it is clear that many of the modified residues are at the interface with the catalytic subunit and could thereby influence the p110 activity ([Figure S7](#app3){ref-type="sec"}). There are several phosphorylation sites in the cSH2. One of them is the Tyr688 in p85α, whose phosphorylation by the Src family kinases leads to upregulation of PI3K activity, and this activation is reversed by dephosphorylation of Tyr688 by Shp1 ([@bib13; @bib9]). Our structure shows that this tyrosine is close to the cSH2/catalytic subunit interface and suggests that its phosphorylation could disinhibit p110β.

Our work illuminates unexpected aspects of p110β inhibition by the p85 regulatory subunit and activation by RTKs. The p85 SH2 domains can contribute to the well-known isoform-dependent specificities in PI3K signaling, despite being shared by all class IA catalytic subunits. Further regulatory complexity that needs to be unraveled is the mechanism of unique regulation of p110β by Gβγ heterodimers.

Experimental Procedures {#sec4}
=======================

Constructs, Design and Cloning {#sec4.1}
------------------------------

Plasmids encoding p110β, p85α, p85β, and p55γ constructs shown in [Table S2](#app3){ref-type="sec"} were generated using the In-Fusion PCR method (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France). The p110β constructs cloned into pFastBac-HTb (Invitrogen Ltd, Paisley, UK) have an N-terminal extension encoded by the vector (MSYHHHHHHDYDIPTTENLYFQGAMDL), comprising a His~6~ tag and a TEV-protease cleavage site. The p85 and p55 constructs cloned into pFastBac1 (Invitrogen) do not have tags. Point mutations in p110β, p85, and p55 constructs shown in [Table S2](#app3){ref-type="sec"} were generated using the Quick-Change protocol (Agilent Technologies UK Ltd., Stockport, Cheshire, UK) and verified by sequencing.

For mammalian expression, pMIG- and pMIR-derived vectors were used ([@bib33]). A myc-tag was inserted at the N terminus of human p110β and a FLAG-tag was inserted at the N terminus of human p85α, using standard PCR and cloning strategy (sequences MEQKLISEEDLGGSTR and MGDYKDDDDKGGSTR ahead of genes). Mutagenesis in p85α was performed in pFastBac1 vectors and subcloned into mammalian expression vectors.

Protein Expression and Purification {#sec4.2}
-----------------------------------

A detailed procedure of protein purification is described in the [Supplemental Experimental Procedures](#app3){ref-type="sec"}. Briefly, proteins were expressed in Sf9 cells, using recombinant baculoviruses. Cells were coinfected for 63 hr with viruses encoding the catalytic and regulatory subunits. Cells were lysed by sonication and the protein complexes were purified by sequential chromatography on HisTrap, Q-Sepharose, heparin, and gel-filtration columns.

Crystallization {#sec4.3}
---------------

Mouse His~6~-p110β(1-1064)/p85β-icSH2(423-722) complex was diluted to 4 mg/ml, mixed with 20 mM (final concentration) sodium phenyl phosphate (Sigma P-7751) and 150 μM of the PI3K inhibitor GDC0941 ([@bib18]). The initial crystallization conditions were obtained from a broad screen of 1056 conditions ([@bib48]) in 96-well MRC crystallization plates (SWISSCI AG, Zug, Switzerland). Additives (GDC0941 and phenyl phosphate) were identified by differential scanning fluorimetry (see [Supplemental Experimental Procedures](#app3){ref-type="sec"}). Optimal crystals were obtained at 22°C in hanging drops over reservoirs of 24-well plates (Hampton Research, Aliso Viejo, CA) containing 12% polyethylene glycol 3350, 0.1 M potassium citrate at pH 6, and 0.4 M lithium sulfate. The drops contained 1 μl each of protein and reservoir solutions. The crystals were cryoprotected by stepwise addition of cryoprotectants consisting of the reservoir solution with 20 mM sodium phenyl phosphate, 150 μM of GDC0941, and an increasing concentration of glycerol up to 20% (in 5% increments). Crystals were flash frozen in liquid nitrogen.

Data Collection and Structure Determination {#sec4.4}
-------------------------------------------

See [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Kinase Assays {#sec4.5}
-------------

See [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Mammalian Cell Culture and Western Blots {#sec4.6}
----------------------------------------

See [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Accession Numbers {#app1}
=================

Coordinates and structure factor amplitudes for the p110β/p85β crystal structure have been deposited in the Protein Data Bank under ID code 2y3a ([Table 1](#tbl1){ref-type="table"}).

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Supplemental References, Seven Figures, and Two TablesMovie S1. Model of PI3K Beta Activation on MembranesMovie S2. Differential Mode of p110β Disinhibition by Phosphopeptide for the nSH2 and cSH2Movie S2 shows a model of nSH2 and cSH2 release from p110β by pY phosphopeptides (pY shown as yellow spheres). The pY binding site on the nSH2 is at the interface with p110β, whereas the pY binding site on the cSH2 is exposed. Phosphopeptides having at least five residues following the pY are necessary to break the contact of the cSH2 with p110β.
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Supplemental Information includes Supplemental Experimental Procedures, Supplemental References, seven figures, two tables, and two movies and can be found with this article online at [doi:10.1016/j.molcel.2011.01.026](10.1016/j.molcel.2011.01.026).

![Inhibition of p110β by p85-Type Regulatory Subunits and Activation of the Complexes by RTK Phosphopeptide\
(A) Domain organization of p110β and the regulatory subunits p85α, p85β, and p55γ. The color scheme for the domains is used for all figures, unless otherwise stated.\
(B) Kinase activity with diC8-PIP~2~/POPS liposomes as a function of enzyme concentration (measured by ADP formation) shows the inhibitory effects of p85β-nicSH2 (nic) and p85β-icSH2 (ic) on the basal activity of p110β. The inhibition is released upon addition of the 10 μM PDGFR pY~2~. The free catalytic subunit (ΔABD-p110β) is more active than any complex. The y axis is expressed as a change in fluorescence polarization (ΔmP), which is obtained by subtracting the observed polarization for the construct at a given enzyme concentration from the maximum fluorescence polarization for that construct. The plateau in these assays arises due to the competitive nature of the ADP detection system, based on displacement of ADP-Alexa 633 tracer from the ADP^2^-antibody by ADP generated during the PI3K assay (see [Supplemental Experimental Procedures](#app3){ref-type="sec"}). All measurements were done in triplicates, and the error bars indicate the standard error of the mean (SEM).\
(C) Kinase activity of p110β/p85β complexes with monomeric substrate (75 μM diC8-PIP~2~) in the presence and absence of pY~2~; y axis as in (B).\
(D) Basal- and pY~2~-stimulated activities of 35 nM PI3K complexes in the absence of lipids (ATP hydrolysis). Activities are given as percent of ATP converted to ADP using the Transcreener assay. Bars indicate SEM.](gr1){#fig1}

![Structure of p110β in Complex with p85β-icSH2\
(A) Cartoon representation of the p110β/p85β-icSH2 complex with GDC0941 (light blue sticks). Views from the front and side (turned 90°) are shown. The ordered activation loop is colored in magenta and the catalytic loop in black.\
(B) Detailed view of the contacts between the p85β-cSH2 and the C-lobe of the kinase domain. The main contact residue Tyr677-p85β (red) interacts with Ser1046-p110β (magenta) and the hydrophobic groove (pale green) formed by two "arms," Kα7/Kα8 (yellow) and Kα11/Kα12 (orange). Dashed black line is a potential hydrogen bond between Tyr677-p85β and Ser1046-p110β.\
(C) Cartoon of the p110β Kα7/Kα8 "arm" (yellow) superimposed on p110α (green) and p110δ (magenta), suggesting a steric clash between cSH2 protrusion (674-AlaGluPro-676) (red stick) and Kα7/Kα8 loop of p110α.\
(D) Cartoon of the cSH2 binding to RTK phosphopeptide, modeled as in the crystal structure of free cSH2 in complex with a PDGFR phosphopeptide (magenta; PDB ID: 1H9O).\
(E) Effects of different RTK phosphopeptides (10 μM) on activity of niSH2 and icSH2 complexes with p110β (1 nM), showing selective requirement for peptides longer than pY + 4 for disinhibition of the cSH2. Error bars indicate SEM.](gr2){#fig2}

![Mutation Y677A in p85β-cSH2 Releases Inhibitory Effect on p110β\
(A) Kinase activity (ADP formation) of p110β in a complex with p85β-icSH2-Y677A (Y677A-ic) compared to the wild-type complex (ic) in the absence and presence of 10 μM PDGFR pY~2~ (ADP formation on the y axis expressed as in [Figure 1](#fig1){ref-type="fig"}B).\
(B) Comparison of p110β activities of 1 nM complexes with wild-type or Y677 mutant nicSH2 or icSH2 (activity shown as in [Figure 1](#fig1){ref-type="fig"}D).](gr3){#fig3}

![cSH2 Is Important for p110β Inhibition In Vitro and in Cells\
(A) Kinase activity of human p110β and icSH2 wild-type constructs from three human regulatory subunits (p85α, p85β, and p55γ) in the absence and presence of 10 μM PDGFR pY~2~ (y axis as in [Figure 1](#fig1){ref-type="fig"}B). EC~50~s for wild-type and icSH2 tyrosine mutants, in the absence and presence of 10 μM PDGF pY~2~, are shown.\
(B) Western blots of HEK cells transiently expressing wild-type and mutant human p110β/p85α. The membrane was probed with antibodies against PKB, pPKB (pSer473), myc (p110β), FLAG (p85α), and actin. Bar graphs show mean ± SEM (n = 3) of PKB phosphorylation level normalized to wild-type p110β/p85α (WT). The position of the three mutations is mapped on the p110β/p85β structure.](gr4){#fig4}

![Truncation of the C Terminus in p110β Decreases Its Activity for Lipid Substrates and Increases ATP Hydrolysis in the Absence of Lipids\
(A) The p110β kinase domain has the signatures of an inactive conformation: C-terminal Kα12 helix folds over the activation loop and His915 (from the DRH motif) points away from the active site (orange). They differ from the same elements in the presumably active conformation of Vps34 (yellow) (PDB: 2X6H).\
(B) Lipid kinase activity (ADP formation) of the wild-type p110β/p85α, in comparison with a truncation mutant lacking 17 residues from the p110β C terminus (ΔCter) and a kinase-dead mutant (D913N). Activities were determined in the absence and presence of 10 μM PDGFR pY~2~. For the D913N mutant, the EC~50~ was too high to be determined accurately (y axis as in [Figure 1](#fig1){ref-type="fig"}B).](gr5){#fig5}

![Structural Basis for p110β Regulation by p85β-iSH2 Domain\
(A) Close-up of interactions between p85β-iSH2 (blue) and p110β activation loop.\
(B) Stereo view of the unique interaction between the iSH2 (blue) with the ABD-RBD linker of p110β (orange), as compared to p110α (white).\
(C) Detailed interactions between residues in the iSH2 (green sticks) with residues in the C2 domain of p110β (magenta sticks). The CBR3 (Cβ5/Cβ6 loop) and Cβ7/Cβ8 loops that contact the iSH2 are highlighted in yellow and pink, respectively.](gr6){#fig6}

![A "Three-Brake" Regulatory Model for Inhibition of p110β Basal Activity\
Model of the "three-brake" inhibition of p110β activity by the nSH2, iSH2, and cSH2 domains of p85. All three domains make inhibitory interactions with the catalytic subunit. The nSH2 and cSH2 are in contact with the "regulatory square" formed by the three C-terminal helices of p110β (Kα10--Kα12). This "regulatory square" encloses the catalytic and activation loop and could mediate the SH2 inhibitory effects. RTK phosphopeptide binding to SH2 domains relieves the inhibition. The main contact between nSH2 and catalytic subunit overlaps perfectly with pY-binding site on nSH2, but not on cSH2. Therefore, relief from cSH2 inhibition requires an extended pYXXM motif.](gr7){#fig7}

###### 

Data Collection and Refinement Statistics

  Data Collection      
  -------------------- ---------------------
  Space group          P6~5~22
  Cell dimensions      
   *a*, *b*, *c* (Å)   134.3, 134.3, 428.1
   α, β, γ (°)         90, 90, 120
  Resolution (Å)       3.3 (3.5--3.3)
  R~sym~ or R~merge~   0.099 (0.674)
  *I* / σ*I*           10.4 (1.9)
  Completeness (%)     98.9 (99.9)
  Redundancy           5.2 (5.4)
                       
  **Refinement**       
                       
  Resolution (Å)       44--3.3 (3.4--3.3)
  No. reflections      34250 (2651)
  R~work~/R~free~      0.24/0.3 (0.26/0.3)
  No. atoms            9848
   Protein             9813
   Ligand/ion          35
   Water               0
  B factors            129
   Protein             129
   Ligand/ion          97
   Water               0
  Rmsds                
   Bond lengths (Å)    0.01
   Bond angles (°)     1.33

The numbers in parentheses refer to statistics for the highest-resolution bin.

[^1]: These authors contributed equally to this work
